Skip to content
BidBenchmark

Contract award

GLYPHIC BIOTECHNOLOGIES, INC.

MEDICAL R AND D PURCHASE ORDER FOR A DHA STTR PHASE I, PROPOSAL NO. H23C-001-0042, TITLED, "DEVELOPMENT OF ANTI-GLYCAN ANTIBODIES AGAINST MULTI-DRUG RESISTANT ESKAPE WOUND PATHOGENS"
PIID
HT942524P0042
Award key
CONT_AWD_HT942524P0042_9700_-NONE-_-NONE-
Recipient UEI
F57WT7JZDH19
Source as of
Current award value
$249,9933
Obligated to date
$249,9932
Potential with options
$249,9933
Awarding agency
Department of DefenseDefense Health Agency
Place of performance
New York, New York
Set-aside
Small Business Set-Aside - Total
Pricing
Firm Fixed Price
Competition
Full and Open Competition after Exclusion of Sources2 offers received
Period of performance
Apr 8, 2024Nov 7, 2024Through Nov 7, 2024 if all options are exercised
Benchmark category
Unclassified

Transaction history

Every action recorded against this award, in the order the government reported them.

ModAction dateReasonObligationValue at action
0Apr 8, 2024Initial award$249,993.28$249,993.28

Provenance

Which source record produced each displayed rollup figure.

FieldSourceFileRetrievedParserArtifact hash
awarding_agency_idUSAspending.govAug 19, 2026usaspending_contract_csv@2026.08.2c65131c143f4
contractor_idUSAspending.govAug 19, 2026usaspending_contract_csv@2026.08.2c65131c143f4
current_award_valueUSAspending.govAug 19, 2026usaspending_contract_csv@2026.08.2c65131c143f4
naics_codeUSAspending.govAug 19, 2026usaspending_contract_csv@2026.08.2c65131c143f4
potential_award_valueUSAspending.govAug 19, 2026usaspending_contract_csv@2026.08.2c65131c143f4
psc_codeUSAspending.govAug 19, 2026usaspending_contract_csv@2026.08.2c65131c143f4
total_obligatedUSAspending.govAug 19, 2026usaspending_contract_csv@2026.08.2c65131c143f4

Sources and method

Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.

This page is a record of one federal award, assembled from the transactions the government published against it. Note 1 describes where the rollup came from. Values are award values, not unit prices.

  1. 1Rollup values derive from 1 transaction records parsed from USAspending.gov, retrieved Aug 19, 2026 by transform awards@2026.08.1.
  2. 2Obligations are the sum of signed federal action obligations across all transactions; deobligations are negative and remain negative.
  3. 3Current and potential award values are taken from the latest reported action, not summed across modifications.
HT942524P0042 — GLYPHIC BIOTECHNOLOGIES, INC. · BidBenchmark